http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110698367-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-29 |
| filingDate | 2019-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110698367-B |
| titleOfInvention | A kind of N-(1-substituted naphthyl)-4-methoxybenzenesulfonamide compound and its preparation and application |
| abstract | The invention discloses a N-(1-substituted naphthyl)-4-methoxybenzenesulfonamide compound, which acts on breast cancer, and its preparation and application. The method 4-methoxybenzenesulfonyl chloride Be raw material, at first with 4-bromo-1-naphthylamine, then prepare the target product of VI series through Suzuki reaction; N-(1-naphthyl)-4-methoxybenzenesulfonamide compounds of the present invention show Certain antitumor activity. According to the test results of anti-tumor activity, compounds VI 01 and VI10 showed biological activities equivalent to or even better than that of the positive control drug C188-9; among them, compound VI 10 with the best activity had the best activity on A549 with high STAT3 expression, MDA-MB- 231, and HCT‑116 showed excellent activity (IC50=4.13～6.55μM), and was superior to the positive control C188‑9. |
| priorityDate | 2019-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.